Demonstrate Efficacy and Safety of Metastatic Breast Cancer
Phase 3
Completed
NCT01084876
| Condition | Metastatic Breast Cancer |
|---|
| Phase | Phase 3 |
|---|
| Sponsor | Celltrion |
|---|
| Status | Completed |
|---|
| Enrollment | 475 participants |
|---|
| Interventions | CT-P6, Herceptin, Paclitaxel |
|---|
| Start date | Jun, 2010 |
|---|
| Completion date | Jul, 2012 |
|---|
| Results posted | Feb 11, 2025 |
|---|
Summary
The purpose of the study is to demonstrate equivalence
Objective Response Rate
6 months (up to 24 weeks) · Participants
| CT-P6 | 138 Participants |
|---|
| Herceptin | 143 Participants |
|---|
| Risk Difference (RD) | -0.0535 (95% CI -0.143–0.036) |
|---|
Open in BENITIONS
View on ClinicalTrials.gov
All trials
This page summarises publicly available data from ClinicalTrials.gov. It is not medical advice and not investment advice. Always consult a qualified healthcare professional.